Scholarlink

<p>The current study focuses on the isolation of a thermophilic fungus capable of biotransforming meloxicam to produce novel metabolites with potential tankyrase inhibitory properties. The isolated strain is identified as <i>Rhizomucor pusillus</i>, confirmed through both morphological and molecular methodologies. The biotransformation process was monitored using high-performance liquid chromatography (HPLC) in conjunction with a two-stage fermentation approach. Previous research, along with LC–MS/MS analyses, has successfully characterized the metabolites generated, providing structural validation. This fungus enabled the conversion of meloxicam into four metabolites: 5-hydroxy methyl meloxicam (M1), 5-carboxy meloxicam (M2), and two previously unreported metabolites (M3 and M4), under controlled conditions of pH 6.0 and a temperature of 40&#xa0;°C over a 3-day shaking culture period. The fungal strain <i>R</i>. <i>pusillus</i> has demonstrated the ability to generate notable metabolites of meloxicam, particularly M1 and M2, as evidenced by research conducted on mammals. Moreover, in silico analyses have revealed the presence of two novel metabolites that may inhibit tankyrase-2. This finding indicates that <i>R. pusillus</i> possesses an enzymatic system comparable to that found in mammals, facilitating the environmentally sustainable and economically viable production of metabolites. Additionally, this strain is capable of synthesizing substantial amounts of metabolites that could potentially exhibit pharmacological effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fungal mediated production of novel metabolites of meloxicam and their tankyrase-2 inhibition potentials: an in silico study

  • 期刊论文

  • 发表日期：

    2025年2月28日

查看全文
  • Srisailam Keshetti,
  • Gurram Shyam Prasad

摘要

The current study focuses on the isolation of a thermophilic fungus capable of biotransforming meloxicam to produce novel metabolites with potential tankyrase inhibitory properties. The isolated strain is identified as Rhizomucor pusillus, confirmed through both morphological and molecular methodologies. The biotransformation process was monitored using high-performance liquid chromatography (HPLC) in conjunction with a two-stage fermentation approach. Previous research, along with LC–MS/MS analyses, has successfully characterized the metabolites generated, providing structural validation. This fungus enabled the conversion of meloxicam into four metabolites: 5-hydroxy methyl meloxicam (M1), 5-carboxy meloxicam (M2), and two previously unreported metabolites (M3 and M4), under controlled conditions of pH 6.0 and a temperature of 40 °C over a 3-day shaking culture period. The fungal strain R. pusillus has demonstrated the ability to generate notable metabolites of meloxicam, particularly M1 and M2, as evidenced by research conducted on mammals. Moreover, in silico analyses have revealed the presence of two novel metabolites that may inhibit tankyrase-2. This finding indicates that R. pusillus possesses an enzymatic system comparable to that found in mammals, facilitating the environmentally sustainable and economically viable production of metabolites. Additionally, this strain is capable of synthesizing substantial amounts of metabolites that could potentially exhibit pharmacological effects.